Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is.

Slides:



Advertisements
Similar presentations
Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Advertisements

Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation  Frans M. Verduyn Lunel,
Serial Profile of Vitamins and Trace Elements during the Acute Phase of Allogeneic Stem Cell Transplantation  Yasuhito Nannya, Akihito Shinohara, Motoshi.
Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome 
Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.
Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients  Takahiro.
Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.
Eosinophils from Hematopoietic Stem Cell Recipients Suppress Allogeneic T Cell Proliferation  Jennie Andersson, Julia Cromvik, Madeleine Ingelsten, Christine.
Yumi Matsuzaki, Kentaro Kinjo, Richard C Mulligan, Hideyuki Okano 
Vaccination of Children following Allogeneic Stem Cell Transplantation
Early Cytomegalovirus Reactivation Leaves a Specific and Dynamic Imprint on the Reconstituting T Cell Compartment Long-Term after Hematopoietic Stem Cell.
Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.
Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells.
Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Up-regulation of NK Cell Activating Receptors Following Allogeneic Hematopoietic Stem Cell Transplantation under a Lymphodepleting Reduced Intensity Regimen.
Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute.
Growth and Differentiation Advantages of CD4+OX40+ T Cells from Allogeneic Hematopoietic Stem Cell Transplantation Recipients  Takero Shindo, Takayuki.
Elevated Numbers of Immature/Transitional CD21− B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host.
R. Handgretinger, X. Chen, M. Pfeiffer, M. Schumm, I. Mueller, T
Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic.
Long-Term Immune Reconstitution of Naive and Memory T Cell Pools after Haploidentical Hematopoietic Stem Cell Transplantation  Rita I. Azevedo, Maria.
Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation 
Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome  Caroline Pical-Izard, Roberto.
Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,
Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.
Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of 533 Adult Patients Who Underwent Transplantation at.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children  Imke Heleen Bartelink, Svetlana.
Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources  Christopher M. Walker,
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases  Elizabeth O. Stenger, Kuang-Yueh Chiang, Ann.
Biology of Blood and Marrow Transplantation
Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies  Stefan O. Ciurea, Richard.
Reconstitution of Interleukin-17–Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation  Felix Bahr, Rebekka Wehner, Uwe Platzbecker,
B Cells and Transplantation: An Educational Resource
Kasiani C. Myers, Stella M. Davies 
Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients  LeAnne Kennedy, Marie Cavalier,
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with β Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic.
Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation.
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Adaptive Natural Killer Cell and Killer Cell Immunoglobulin–Like Receptor–Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated.
Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with a Reduction in Ploidy and an Immaturation.
Allogeneic Stem Cell Transplantation for Aplastic Anemia
High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
What is quality in a transplant program?
Possible Impact of Cytomegalovirus-Specific CD8+ T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell.
Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome 
Recovery of Circulating T-Follicular Helper Cells after Hematopoietic Stem Cell Transplantation  Edouard Forcade, MD, Steven Paula, Kristen Cowens, Marta.
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV?  Marie von Lilienfeld-Toal, MD, Maria Gilleece,
Outcome of Donor Lymphocyte Infusion after T Cell–depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic.
Nonmyeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia  Jennifer Clay, Austin G. Kulasekararaj,
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell.
Sara C. Meyer, Alix O’Meara, Andreas S. Buser, André Tichelli, Jakob R
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Immunologic Recovery in Children after Alternative Donor Allogeneic Transplantation for Hematologic Malignancies: Comparison of Recipients of Partially.
Real Time Immunophenotyping of Leukocyte Subsets Early after Double Cord Blood Transplantation Predicts Graft Function  Jianqiang Li, Ian Nicoud, Joseph.
A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation  Mark H. Kirschbaum,
Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation  Abir Bhattacharyya, Laïla-Aïcha.
Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell.
In Memoriam: E. Donnall Thomas
Optimal Donor Selection: Beyond HLA
Presentation transcript:

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells  Francesco Grimaldi, Victoria Potter, Pilar Perez-Abellan, John P. Veluchamy, Muhammad Atif, Rosemary Grain, Monica Sen, Steven Best, Nicholas Lea, Carmel Rice, Antonio Pagliuca, Ghulam J. Mufti, Judith C.W. Marsh, Linda D. Barber  Biology of Blood and Marrow Transplantation  Volume 23, Issue 2, Pages 293-299 (February 2017) DOI: 10.1016/j.bbmt.2016.11.003 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Serial analysis of peripheral blood chimerism and lymphocyte composition after FCC HSCT. (A) Percentage donor chimerism of unfractionated, purified CD3 and purified CD15 peripheral blood cells. Mean and SEM are shown. (B) Reconstitution of peripheral blood lymphocytes after FCC HSCT. Median and interquartile range are shown, and the horizontal dotted lines enclosing gray boxes represent the median and interquartile range of 11 adult healthy volunteers. Comparisons between cell numbers at each time point and healthy volunteers were performed using a 2-tailed Mann-Whitney U test. Lymphocyte numbers at all time points were significantly below numbers for healthy volunteers (P < .0005). (C) Percentage of NK, B, and T cells. Mean and SEM are shown, and values for 11 adult healthy volunteers (HV) are indicated. (D) Percentage of CD4 and CD8 T cells within the CD3 T cell population using mean values. (E) Percentages of naïve, memory, and effector subset composition of CD4 T cells (left) and CD8 T cells (right). Mean and SEM are shown, and values for 11 adult healthy volunteers (HV) are indicated. Biology of Blood and Marrow Transplantation 2017 23, 293-299DOI: (10.1016/j.bbmt.2016.11.003) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Analysis of individual patients showed sustained mixed T cell chimerism at 1 year after FCC HSCT is due primarily to persistence of recipient CD8 T cells, with notable contribution of the effector subset. (A) Panels illustrate the gating strategy used for isolation of naïve, memory, and effector T cell subsets by FACS. (B) CD4 T cell (left) and CD8 T cell (right) subset chimerism at 1 year for 5 patients. CMV serostatus of donor/recipient and reactivation early post HSCT: patient 1, negative/negative; patient 2, negative/positive no reactivation; patient 3, positive/negative and reactivation; patient 4, negative/positive and reactivation; patient 5, negative/positive no reactivation. Biology of Blood and Marrow Transplantation 2017 23, 293-299DOI: (10.1016/j.bbmt.2016.11.003) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions